Mereo Biopharma Group Plc ADR (MREO) concluded trading on 01/11/24 at a closing price of $2.82, with 2.71 million shares of worth about $7.65 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 115.27% during that period and on Thursday the price saw a gain of about 1.81%. Currently the company’s common shares owned by public are about 128.39M shares, out of which, 128.39M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 4 analysts are covering the MREO stock and their offered price forecasts bring an average price target of $4.25. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $5.00 and could fall to a lowest price of $4.00. The stock’s current price level is 33.65% above of average price target set by the analysts, while a rise to estimated low would result in gain of 29.5% for the stock. However, touching the estimated high of $5.00 would mean a gain of 43.6% for the stock.
However, the stock later moved at a day high price of 2.8500, or with a gain of 1.81%. Stock saw a price change of 13.25% in past 5 days and over the past one month there was a price change of 41.71%. Year-to-date (YTD), MREO shares are showing a performance of 22.08% which increased to 228.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.69 but also hit the highest price of $2.80 during that period. The average intraday trading volume for Mereo Biopharma Group Plc ADR shares is 1.36 million. The stock is currently trading 23.60% above its 20-day simple moving average (SMA20), while that difference is up 30.79% for SMA50 and it goes to 89.68% higher than SMA200.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) currently have 128.39M outstanding shares and institutions hold larger chunk of about 56.50% of that.
The stock has a current market capitalization of $362.06M and its 3Y-monthly beta is at 0.79. It has posted earnings per share of -$0.25 in the same period. It has Quick Ratio of 3.11 while making debt-to-equity ratio of 0.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MREO, volatility over the week remained 9.35% while standing at 6.79% over the month.
Analysts are in expectations that Mereo Biopharma Group Plc ADR (MREO) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 31.56% while it is estimated to increase by 91.77% in next year.
Analysts at 4 brokerage firms have issued recommendations for the Mereo Biopharma Group Plc ADR (MREO)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 4 Wall Street analysts, 4 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on October 13, 2023 offering a Buy rating for the stock and assigned a target price of $4 to it.
